Thyroid eye disease (TED)

Active Ingredient: Teprotumumab

Indication for Teprotumumab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Teprotumumab is indicated in adults for the treatment of moderate to severe thyroid eye disease (TED).

For this indication, competent medicine agencies globally authorize below treatments:

10 mg/kg for the initial dose followed by 20 mg/kg of body weight for 7 additional doses given once every 3 weeks

For:

Dosage regimens

Intravenous, 10 milligrams teprotumumab per kilogram of body weight, one dose, over the duration of 3 weeks. Afterwards, intravenous, 20 milligrams teprotumumab per kilogram of body weight, once every 3 weeks, 7 doses in total.

Detailed description

Dosing is based on the patient's actual body weight. The recommended dose is 10 mg/kg of body weight for the initial dose followed by 20 mg/kg of body weight for 7 additional doses given once every three weeks as an intravenous infusion.

For the first 2 infusions, the diluted solution is administered as an intravenous infusion over at least 90 minutes. If well tolerated, infusions 3 to 8 can be administered over 60 minutes every three weeks. Clinical response is expected with 8 doses of treatment. Additional doses should not be administered if response is not achieved with this regimen.

Recommended pre-medication

For patients experiencing immediate hypersensitivity reactions or infusion-related reactions during the first two infusions of teprotumumab, pre-medication with an antihistamine, antipyretic, corticosteroid products and/or administering all subsequent infusions at a slower infusion rate is recommended.

Dosage considerations

Teprotumumab must be administered as an intravenous infusion.

Teprotumumab must not be co-administered with other medicinal products through the same infusion line.

Active ingredient

Teprotumumab

Teprotumumab mechanism of action in patients with thyroid eye disease has not been fully characterised. Teprotumumab binds to IGF-1R and blocks its activation and signalling.

Read more about Teprotumumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.